# Amyris

the Emeryville synthetic-biology firm built a Lab-to-Market platform turning plant sugars into molecules like squalane and ambroxide, amassing about 700 patents and 16 products before a 1.15-billion-dollar debt crisis drove a 2023 Chapter 11 reorganization and a pivot to B2B ingredient supply.

Source: https://en.bioecon.ru/companies/amyris/
Updated: 2026-08-15

- Country: United States
- Ticker: AMRS

## Technologies

- [Biosynthetic specialty & fine chemicals (precision fermentation, biocatalysis, biorefinery)](https://en.bioecon.ru/technology/biosynthetic-specialty-chemicals/)
- [Terpenes & terpenoids as platform molecules](https://en.bioecon.ru/technology/terpenes-terpenoids-platform-molecules/)